Tags

Type your tag names separated by a space and hit enter

Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation.
Antimicrob Agents Chemother. 2005 Jun; 49(6):2302-6.AA

Abstract

A total of 195 Mycoplasma pneumoniae strains were isolated from 2,462 clinical specimens collected between April 2002 and March 2004 from pediatric outpatients with respiratory tract infections. Susceptibilities to six macrolide antibiotics (ML), telithromycin, minocycline, levofloxacin, and sitafloxacin were determined by the microdilution method using PPLO broth. A total of 183 M. pneumoniae isolates were susceptible to all agents and had excellent MIC90s in the following order: 0.00195 microg/ml for azithromycin and telithromycin, 0.0078 microg/ml for clarithromycin, 0.0156 microg/ml for erythromycin, 0.0625 microg/ml for sitafloxacin, 0.5 microg/ml for minocycline, and 1 microg/ml for levofloxacin. Notably, 12 ML-resistant M. pneumoniae strains were isolated from patients with pneumonia (10 strains) or acute bronchitis (2 strains). These strains showed resistance to ML with MICs of >or=1 microg/ml, except to rokitamycin. Transition mutations of A2063G or A2064G, which correspond to A2058 and A2059 in Escherichia coli, in domain V on the 23S rRNA gene in 11 ML-resistant strains were identified. By pulsed-field gel electrophoresis typing, these strains were classified into groups I and IIb [corrected] as described previously (A. Cousin-Allery, A. Charron, B. D. Barbeyrac, G. Fremy, J. S. Jensen, H. Renaudin, and C. Bebear, Epidemiol. Infect. 124:103-111, 2000). These findings suggest that excessive usage of MLs acts as a trigger to select mutations on the corresponding 23S rRNA gene with the resultant occurrence of ML-resistant M. pneumoniae. Monitoring ML susceptibilities for M. pneumoniae is necessary in the future.

Authors+Show Affiliations

Laboratory of Infectious Agents Surveillance, Kitasato Institute for Life Sciences, Kitasato University, 5-9-1 Shirokane, Minatoku, Tokyo, 108-8641 Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15917525

Citation

Morozumi, Miyuki, et al. "Emergence of Macrolide-resistant Mycoplasma Pneumoniae With a 23S rRNA Gene Mutation." Antimicrobial Agents and Chemotherapy, vol. 49, no. 6, 2005, pp. 2302-6.
Morozumi M, Hasegawa K, Kobayashi R, et al. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob Agents Chemother. 2005;49(6):2302-6.
Morozumi, M., Hasegawa, K., Kobayashi, R., Inoue, N., Iwata, S., Kuroki, H., Kawamura, N., Nakayama, E., Tajima, T., Shimizu, K., & Ubukata, K. (2005). Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrobial Agents and Chemotherapy, 49(6), 2302-6.
Morozumi M, et al. Emergence of Macrolide-resistant Mycoplasma Pneumoniae With a 23S rRNA Gene Mutation. Antimicrob Agents Chemother. 2005;49(6):2302-6. PubMed PMID: 15917525.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. AU - Morozumi,Miyuki, AU - Hasegawa,Keiko, AU - Kobayashi,Reiko, AU - Inoue,Nagako, AU - Iwata,Satoshi, AU - Kuroki,Haruo, AU - Kawamura,Naohisa, AU - Nakayama,Eiichi, AU - Tajima,Takeshi, AU - Shimizu,Kouichi, AU - Ubukata,Kimiko, PY - 2005/5/27/pubmed PY - 2005/7/27/medline PY - 2005/5/27/entrez SP - 2302 EP - 6 JF - Antimicrobial agents and chemotherapy JO - Antimicrob Agents Chemother VL - 49 IS - 6 N2 - A total of 195 Mycoplasma pneumoniae strains were isolated from 2,462 clinical specimens collected between April 2002 and March 2004 from pediatric outpatients with respiratory tract infections. Susceptibilities to six macrolide antibiotics (ML), telithromycin, minocycline, levofloxacin, and sitafloxacin were determined by the microdilution method using PPLO broth. A total of 183 M. pneumoniae isolates were susceptible to all agents and had excellent MIC90s in the following order: 0.00195 microg/ml for azithromycin and telithromycin, 0.0078 microg/ml for clarithromycin, 0.0156 microg/ml for erythromycin, 0.0625 microg/ml for sitafloxacin, 0.5 microg/ml for minocycline, and 1 microg/ml for levofloxacin. Notably, 12 ML-resistant M. pneumoniae strains were isolated from patients with pneumonia (10 strains) or acute bronchitis (2 strains). These strains showed resistance to ML with MICs of >or=1 microg/ml, except to rokitamycin. Transition mutations of A2063G or A2064G, which correspond to A2058 and A2059 in Escherichia coli, in domain V on the 23S rRNA gene in 11 ML-resistant strains were identified. By pulsed-field gel electrophoresis typing, these strains were classified into groups I and IIb [corrected] as described previously (A. Cousin-Allery, A. Charron, B. D. Barbeyrac, G. Fremy, J. S. Jensen, H. Renaudin, and C. Bebear, Epidemiol. Infect. 124:103-111, 2000). These findings suggest that excessive usage of MLs acts as a trigger to select mutations on the corresponding 23S rRNA gene with the resultant occurrence of ML-resistant M. pneumoniae. Monitoring ML susceptibilities for M. pneumoniae is necessary in the future. SN - 0066-4804 UR - https://www.unboundmedicine.com/medline/citation/15917525/Emergence_of_macrolide_resistant_Mycoplasma_pneumoniae_with_a_23S_rRNA_gene_mutation_ L2 - https://journals.asm.org/doi/10.1128/AAC.49.6.2302-2306.2005?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -